The Olympic and Paralympic Games Tokyo 2020 Coming Soon - Tokyo to Accept Media Registrations for the Tokyo Media Center
With the Olympic Games just around the corner, Tokyo Governor Koike Yuriko sent a video message to the world's media inviting them to the Tokyo Media Center (TMC) provided by the Tokyo Metropolitan Government. TMC offers services not only for members of the press coming to Tokyo but also those working from their home countries, a great opportunity to cover the Games and the City online no matter how far away. Registration is required for full use of member services. Do not miss the opportunity to receive regular full online updates about what’s happening in Tokyo during the Games!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005509/en/
Video invitation from Koike Yuriko, Governor of Tokyo (Photo: Business Wire)
Find the video invitation form Koike Yuriko, the Governor of Tokyo at https://tokyo.mediacenter.jp/about/
Register Now!
| 1) |
Access TMC’s registration page at https://tokyo.mediacenter.jp/?modal=register |
|
| 2) |
Submit your name and email for Account Registration. |
|
| 3) |
Register your ID and proof of employment with the Accreditation Application at https://tokyo.mediacenter.jp/login/ |
Benefits of TMC Online Service
|
1) |
TMC Web will be your home for various information during the Games, including photos, videos, data regarding Tokyo and more. |
|
|
2) |
TMC Newsletters will update you twice a day with what’s happening in Tokyo during the Games. |
|
|
3) |
TMC Briefings will live-stream daily briefings from the Tokyo Metropolitan Government. You can cast questions to the officials. They are scheduled from 12:30 pm to 1:00 pm, Japan Standard Time (JST), from July 23 to August 8 and from August 24 to September 5, 2021. |
|
|
4) |
TMC Talks will video-stream daily live presentations and recorded messages by Governor Koike and/or global leaders from various fields such as sports, culture and urban development. The main theme will be the future of Tokyo. You can cast questions to speakers via online tools. More details about TMC Talks will be announced soon. They are scheduled from 2:00 pm to 2:40 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
|
|
5) |
TMC Online Concierge will answer your questions and provide consultations about Tokyo-related coverage and photography. It will be available between 8:00 am and 10:00 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
We are looking forward to serving you soon!
About the Tokyo Media Center (TMC)
The Tokyo Media Center (TMC) has been set up by the Tokyo Metropolitan Government to serve as a media coverage base for domestic and international media during the Olympic and Paralympic Games Tokyo 2020. TMC provides information related to the host city Tokyo as well as the Tokyo 2020 Games. It is totally separate from the Main Press Centre (MPC) and International Broadcast Centre (IBC), which are operated by the Tokyo 2020 Organising Committee.
Website
URL: https://tokyo.mediacenter.jp/
Facilities
|
Date and Time of Opening: |
|
|
Wednesday, July 21, 2021 to Monday, August 9, 8:00 am to 10:00 pm, JST |
|
|
Monday, August 23, 2021 to Sunday, September 5, 8:00 am to 10:00 pm, JST |
|
|
* A pre-opening is scheduled on Monday, July 19 and Tuesday, July 20. The details will be announced separately. |
|
|
Access: |
Tokyo Sports Square, 2nd and 3rd Floor (address: Marunouchi 3-8-3, Chiyoda-ku, Tokyo) |
|
1 minute walk from JR Yurakucho Station and Tokyo Metro Yurakucho Station |
|
|
Services: |
Workspace and lounge |
|
Approximately 120 seats available to create a work environment for journalists. |
|
|
A drink corner offering refreshments will also be provided. |
|
|
Information Desk |
|
|
Staff will respond to inquiries regarding facilities usage. Upon first entrance, guests will receive a media kit which includes complimentary Tokyo-related giveaways. |
|
|
Japan Showcase |
|
|
The Japan National Tourism Organization (JNTO) will have booths to promote Japan’s various regions and traditional culture. |
|
|
Japanese Liquors Booth |
|
|
The National Tax Agency (NTA) will have a booth to introduce Japanese liquors. |
|
|
Internet Connection |
|
|
Wi-fi available for use by registered members. |
|
|
* Detailed information such as COVID-19 countermeasures and how to enter the facilities will be periodically updated on the TMC website and TMC Briefings. |
|
TOKYO UPDATES
Tokyo Metropolitan Government (TMG) launched a new media platform to show the world the ever-changing face of Tokyo now and the future in May 2021. This platform features content such as articles which focus on the attractions of Tokyo and the people who live, study, and work in the city. Please be sure to check it out.
URL: https://www.tokyoupdates.metro.tokyo.lg.jp/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005509/en/
Contact information
About Media Center Registration
Tokyo Media Center Management Office
inquiry@tokyo.mediacenter.jp
Other Inquiries Regarding the TMC
Tokyo 2020 Media Center, Policy Coordination Section, Policy Coordination Division, Office of the Governor for Policy Planning, Tokyo Metropolitan Government
tokyo_media_center@section.metro.tokyo.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom